Bicara Therapeutics is a clinical-stage biopharmaceutical company that brings transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) and a directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b).